Aclarion, Inc.

Aclarion is a healthcare technology company that uses Magnetic Resonance Spectroscopy ("MRS") and proprietary biomarkers to optimize clinical treatments. The company addresses the $134.5B U.S. low back and neck pain market. Aclarion's technology is initially focused on improving outcomes for surgical interventions to treat chronic discogenic low back pain. In this application, the technology assists surgeons in determining the optimal surgical procedure for patients undergoing surgery for pain isolated to their lumbar spine, which consists of the five lower vertebrae, L-1 to L-5. The company currently uses Artificial Intelligence ("AI") to assist in quality control processes by flagging spectroscopy data that indicates a poor MRS study. Aclarion is collecting raw and post-processed spectral data from every Nociscan completed into databases. This data will be used as future training data to teach a machine learning algorithm to associate MRS data with clinical outcomes. The company has limited sales to date.